APRIL 21-24, 2020

VIRTUAL

The Official Blog of the Annual Translational Microbiome Conference

The official blog of the Annual Translational Microbiome Conference provides readers with information, insight and analysis regarding the microbiome.

New Tools are Needed to Drive Microbiome Research to the Next Level

These microbiome insights are brought to you by Dr. Peter Christey of GALT, Inc., and Arrowhead Publishers. Dr. Christey will be presenting "Driving the Tidal Wave of Microbiome Discovery - a Next Generation Platform for Exploring the Microbiome" at Arrowhead's 4th Annual Translational Microbiome Conference, 18th-20th April, 2018.

I so much enjoy microbiome meetings and continue to be blown away by the speed at which the field is developing and the innovative work being presented. However, there is a sense of frustration with many of the presentations and publications we see in the literature. You would have seen them - studies where samples are taken from healthy patients, samples are taken from diseased patients, next generation sequencing of the microbiome is performed and the results are compared. We get shown lots of charts showing that population x goes up, population y goes down. Then of course PCoA and other statistical charts are presented to demonstrate some point or other. All during the presentation I'm waiting for the punch-line, the insight that helps me understand what is going on. What is the microbiome doing? Who are the key actors? How are they impacting the disease state? What is the underlying biology, chemistry here? Data and insights that quench my curiosity. But no, the presentation ends once the sequencing data analysis is complete - we are left with that empty feeling that something is going on, but it is beyond our ability to understand.

Sequencing is an incredibly powerful tool that has helped illuminate the wonderful complexity and richness of the microbiome. It's one of the few, if not the only, research tools we currently have that scales to the complexity of the microbial systems we are studying. But is it enough? I feel we are doing the equivalent of trying to cure cancer solely by sequencing a million tumor samples. Cancer is being defeated by insights derived from multiple avenues of investigation, including clinical trials, epidemiological data, analysis of the underlying genetics and, critically, wet lab work dissecting the core biological mechanisms and pathways. Wet lab work is critical to test hypotheses and new ideas under controlled conditions - the path to getting from correlation to mechanism. Then we can seriously develop informed interventions to improve the human condition.

Microbiome wet lab work is constrained by the current toolset. Mainstream microbiology technologies were invented over 100 years ago. Core tasks, such as isolating target microbes, creating comprehensive strain collections or studying model ecosystems, are often difficult or impractical. We need new tools to drive microbiome research to the next level.

Continue reading
1369 Hits

Gut Bugs May Modulate the Efficacy of Anti-PD1 Immunotherapy

These microbiome insights are brought to you by Dr. Vancheswaran Gopalakrishnan and Dr. Jennifer Wargo of The University of Texas MD Anderson Cancer Center, and Arrowhead Publishers. Dr. Gopalakrishnan will be presenting MD Anderson’s work at Arrowhead’s 4th Annual Translational Microbiome Conference, 18th-20th April, 2018.

Pioneering research performed at the MD Anderson Cancer Center1 suggests that the gut microbiome influences how cancer responds to immunotherapy; potentially creating new opportunities to improve treatment.

Cancer patients who saw no benefit from anti-PD1 checkpoint blockade immunotherapy lacked certain beneficial gut bacteria. On the other hand, cancer patients who responded to anti -PD1 immunotherapy possessed gut bacteria whose abundance in the gut correlated with the presence of cancer-killing T-cells. When the researchers transferred gut bacteria from human cancer patients into germ-free mice using fecal matter transplantation (FMT), the rodents mirrored the patient’s fates.

Anti-PD1 immunotherapy “unleashes the brakes on the immune system” by preventing programmed-death-1 (PD-1) binding to programmed-death ligand-1 (PD-L1) on cancer cells, allowing T-cells to attack. However, anti-PD1 immunotherapy is not effective for all cancer patients and responses are not always durable.

The Answer’s in the Poop!

To assess the impact of the microbiome, the MD Anderson team analysed oral and fecal samples of 112 metastatic melanoma patients undergoing anti-PD1 immunotherapy1. 16rRNA and whole genome sequencing was performed to determine diversity, composition and functional potential of the oral and fecal microbiomes. Baseline tumor and blood samples were also analysed.

While no differences in response or progression were found in connection with the oral samples; the 43 fecal samples told another story. Analysis of the fecal microbiome samples (30 of which were responders and 13 non-responders) found that patients with a greater diversity of bacteria in their gut microbiome at baseline had a longer median progression-free survival (PFS). While the high diversity group had not reached median PFS, intermediate and low diversity groups had median PFS of 232 and 188 days, respectively. 

Additional analysis showed that responding patients with high levels of beneficial Clostridiales/Ruminococcaceae had greater presence of anti-tumor T-cells in their tumors, and higher levels of circulating T cells that kill abnormal cells. On the other hand, patients abundant with Bacteriodales had higher levels of circulating regulatory T cells, myeloid derived suppressor cells and a blunted cytokine response, resulting in diminished anti-tumor immunity.

To investigate causal mechanisms, the team transplanted fecal microbiomes from responding patients and non-responding patients into germ-free mice. Those receiving transplants from responding patients had significantly reduced tumor growth as well as higher densities of beneficial T cells in their gut and tumor sites and lower levels of immune suppressive cells. They also had better outcomes when treated with PD-1 axis blockade

Antibiotics May also Affect Anti-PD1 Immunotherapy  

Interestingly, the MD Anderson’s findings complement those of the Gustave Roussy Cancer Campus, France2. Lung, kidney or bladder cancer patients who received antibiotics to treat infection shortly before or after starting anti-PD1 immunotherapy, did not respond as well to treatment. The presence of Akkermansia muciniphila bacteria in both humans and mice was linked to improved responses to anti- PD1 immunotherapy.

Modulation of the Gut Microbiome Could Improve Cancer Prognosis

Although these findings are early, they suggest the connection between the gut microbiome and immune system could have major implications for cancer treatment and prognosis. Further work is needed to analyse the diversity and composition of the gut microbiome to predict response to anti-PD1 immunotherapy; and to modulate the gut microbiome to enhance treatment.

Research has shown that the human microbiome may be modulated by diet, exercise, probiotic or antibiotic use or FMT – however these need to be carefully studied in clinical trials. 

On that note, the MD Anderson team is now planning a clinical trial using strategies to modulate the gut microbiome in patients with metastatic melanoma going onto anti-PD1 (in collaboration with the Parker Institute for Cancer Immunotherapy and Seres Therapeutics). The primary hypothesis of this trial will be that we can safely modulate the gut microbiome in metastatic melanoma patients going on to anti-PD1 therapy.

Tremendous promise but challenges ahead

These findings have important potential implications, though challenges are also evident.  Several issues have been raised by Dr Jennifer Wargo and Dr Vancehswaran Gopalakrishnan given these results.  “These findings have important implications, but we don’t know all the answers yet. Should we be profiling the gut microbiome of patients going onto immunotherapy? And should we tightly monitor antibiotic use in these patients? Furthermore, what other factors – including diet – may be influencing the microbiome? Should we also be profiling the gut microbiome in pre-clinical models where we are testing therapeutic strategies to fight cancer and other diseases? And finally, can we manipulate the microbiome to improve overall health and to facilitate cancer immunosurveillance?”

In addition to this, strategies such as FMT have their own inherent challenges. Although first documented in 4th century China as ‘yellow soup’; FMT has slowly gained popularity over the past years in the US for the treatment of inflammatory gastrointestinal disorders

FMT as a novel adjuvant cancer therapy could bring many rewards, though poses tough challenges. As a cutting-edge forefront therapy, FMT follows unique regulatory oversight. In May 2013, the FDA announced it would regulate FMT as an Investigational New Drug (IND) and Biologics. This classification restricted physicians to file an IND application to use FMT in a clinical trial. However, both patients and physicians raised concerns this would restrict patient access to FMT.

In June 2013, the FDA responded to these concerns and issued its Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies (http://fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.htm).

Under this ruling, qualified physicians can perform FMT for recurrent C. dfficile not responding to standard treatment outside clinical trials without filing for an IND application.

FMT also has other challenges, given variation between preparations. Ultimately, the MD Anderson team and their collaborators hope to identify a live bacterial product incorporating consortia of bacteria implicated in enhancing immunity and therapeutic responses. Though challenges exist, given the potential far-reaching rewards, these efforts are clearly worth pursuing.

References:

  • Gopalakrishnan V. et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2017 Nov http://dx.doi.org/10.1126/science.aan4236
  • Routy B. et al., Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2017 Nov http://dx.doi.org/10.1126/science.aan3706
  • Matson V. et al., The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 2018 Jan http://doi1126/science.aao3290

#microbiome #Arrowhead #cancer #melanoma   #PD-1 inhibitors #Gopalakrishnan #Wargo #MD Anderson Cancer Center #FMT #FDA #Seres Therapeutics #Parker Institute for Cancer Immunotherapy

Continue reading
1797 Hits

YUN Overcomes European Regulatory Issues Surrounding the Use of Live Probiotic Bacteria for Topical Skin Application

These microbiome insights are brought to you by Dr. Ingmar Claes, Chief Scientific Officer at YUN, and Arrowhead Publishers and Conferences. Dr Claes will be presenting YUN’s work at Arrowhead’s 4th Annual Translational Microbiome Conference, 18th-20th April 2018. (www.microbiomeconference.com).

We all know that the skin is critical for our health by serving as a protective layer against external factors, but we tend to overlook the importance of the skin microbiome. The skin microbiome, acid mantle and epidermal skin barrier functions as our first layer of defense against pathogens. Use of products with live beneficial bacteria, also known as probiotics, pharmabiotics, or live biotherapeutic products (LBPs), have the potential of improving dysbosis for a multitude of skin disorders. Such restoration of the microbiome using ‘live’ probiotic bacteria to treat disorders is known as probiotherapy.

YUN is a Belgian-based biotech company with a totally new vision on health and hygiene. YUN aims to take healthcare to the next level. YUN believes in maintaining and restoring the skin microbiome; and the importance of the microbiome for human health. Working closely with leading probiotherapy experts from the University of Antwerp over the past decade, YUN has developed a world premier range of skin products including treatments for pimples (ACN and ACN+) and athlete’s foot (FNG).

World Premier ACN and ACN+ Products
YUN’s ACN and ACN+ products are the first creams (oil in water cream) in the world that contain ‘live’ probiotic bacteria in a dose that will have an impact on the skin microbiome. This major breakthrough was made possible by the development of an innovative type of microcapsule. This new microcapsule contains the ‘live’ bacteria in a core suspension, surrounded by multiple layers to protect them from the water in the cream. Furthermore, YUN strains are ‘probiotic’ which are specifically selected lactobacilli strains. These have some shared mechanisms of action with other probiotic strains, but also have some very specific properties against a selection of pathogenic or problem-causing micro-organisms such as Propionibacteriuim acnes, Trichiphyton spp, Staphylococcus spp., Malassezia spp., Candida spp.

Tough Regulatory Approval Challenges
LBP products face tough regulatory hurdles. Unlike the US in which the FDA’s Center for Biologics Evaluation and Research (CBER) has issued LBP guidelines for industry, the EU lacks regulatory framework. Regulations are lagging behind the new innovations. As in all regulations, safety is considered the most important factor. Thus, safety should always be the first concern when using LBPs.

As a completely new field of products for topical application, YUN faced tough European regulatory approval challenges. YUN has been looking from the start to market its products outside the EU, and it is clear that there are differences in regulations between the US and Europe. Indeed, regarding the FDA LPB product guidelines, it is unclear whether YUN’s topical products fall under the FDA’s definition of LBPs.

Further complicating matters is there are major differences between the safety assessment of oral medical drugs and LBPs for topical use. Specifically, for topical application, the challenges regarding safety should not be neglected. Even though our epidermal skin barrier, the acid mantle layer and the skin microbiome seem to be protective for systemic problems, carefully selected safe ‘probiotic’ strains should be selected for topical application.

As YUN’s topical skin care LBP products are safe and work by restoring or maintaining the skin’s natural defense layer, namely the skin microbiome, they fall in the EU under the cosmetic regulations. These products must not cause damage to human health when applied under normal or reasonably foreseeable conditions of use (cfr. Regulation (EC) N° 1223/2009) and data proving the safety of the probiotic strains being used must therefore be provided.
YUN specifically substantiated for the safety of all their topical products, both at the probiotic strain level and the final product itself. YUN goes even one step further as it wants to address the issues at hand of many of the current topical products which neglect safety on the skin microbiome.

Probiotic Strain Safety Research
YUN specifically performed research for the safety of the probiotic strains both in vitro and in vivo. Indeed, Dr Claes emphasized the importance of the safety of YUN’s probiotic strains particularly during the pre-clinical in vitro screening phase of development. Consequently, all the YUN’s strains were thoroughly characterized at the strain level. Mobile antibiotic resistance elements and virulence factors were investigated and excluded. Furthermore, interactions with human cells were also investigated.

Final Product Level Safety Research
At the final product level, aseptic filling, absence of contaminant pathogenic bacteria and amount of ‘live’ probiotic bacteria had to be proven by YUN. Additionally, the products with ’live’ probiotic strains were clinically evaluated by YUN to underline their level of safety for topical application on the skin.

Quality Control Issues
YUN guarantees the viability of its probiotic bacteria through patented breakthroughs in new galenic formulation and the development of microcapsules shielding its ‘live’ probiotics from water present in creams. Keeping the bacteria in a water-free core suspension ensures a minimal viable dose for up to six months at room temperature as the bacteria’s metabolical activity is minimal in the water-free suspension.

New Regulatory Framework is Needed
Dr Claes explains that by constructing the safety documentation and quality controls in the production of YUN’s products, they could be notified to EU authorities and placed safely on the market. It is therefore clear that safety is the most important aspect for LBPs and should always be addressed correctly. The added therapeutic benefits of these products for topical skin application might be the future for addressing specific skin disorders by using carefully selected probiotic strains.

Furthermore, YUN is a member of the Pharmabiotic Research Institute (PRI) and hopes to constructively interact with the European Medicine Agency (EMA). YUN believes that for some specific applications and products a completely new regulatory framework should be proposed for these new innovative products, which in the first place should always tackle safety before efficacy.

Clearly, approval regulation is lagging behind innovation. European drug authorities must tackle regulatory challenges to produce concise guidelines for industry in the development of LBPs. YUN deserves much credit for not only developing the world’s first ‘live’ probiotic creams in a dose to maintain and restore the skin microbiome, but overcoming tough European regulatory approval challenges.

Continue reading
3706 Hits

Analysis of the Human Microbiome Pipeline: Promising Opportunities to Develop Innovative Products

The human microbiome is an exciting revolutionary space which is captivating the interest of academia and industry alike. Consequently, the current human microbiome pipeline is emerging as a red- hot space with promising opportunities to develop innovative products.

The human microbiome pipeline can be divided into two major applications; therapeutics and diagnostic products. To date, no human microbiome therapeutic or diagnostic product has gained regulatory approval, leaving investors everything to play for. Pipeline therapeutics which modulate the human microbiome include fecal microbiota transplant (FMT), small molecules and live microbes. The human microbiome therapeutic pipeline encompasses a broad range of diseases including cancer, diabetes, asthma, atherosclerosis, nutrition, arthritis, neurological disorders and clostridium difficile infection (CDI). Currently, the human microbiome therapeutic pipeline involves a heated race-to-market for the treatment of CDI, featuring three late- stage products.

Rebiotix’s RBX2660 delivers live, human-derived microbes via enema into the Gl tract for treatment of recurrent CDI.  Rebiotix recently announced it has begun its Phase III trial. Rebiotix’s Phase II trial, known as PUNCH CD found overall efficacy of RBX2660 at treating recurrent CDI was 87%. The Phase IIb PUNCH-CD 2 trial found efficacy was 88%; while the open-label Phase II trial, PUNCH Open Label, showed efficacy was 79% compared with a historical control of 52% (p<0.000). RBX2660 was found to be safe and well tolerated. RBX2660 has been granted FDA Fast Track, Orphan Drug and Breakthrough Therapy designations.

Seres Therapeutics/Nestlé Health Science’s SER-109 is a single-dose oral capsule consisting of bacterial spores enriched and purified from stool samples of healthy, screened human donors. In June 2017, SER-109 commenced its Phase III trial (ECOSPOR III) for the prevention of recurrent CDI. Phase /II results at eight weeks found 97% of patients achieved a clinical cure. Additionally, 87% of patients achieved no diarrhea associated with a positive test for C. difficile. ECOSPOR results at 24 weeks found relatively little new efficacy data compared to eight weeks.  The Phase II open-label extension study ECOSPOR II found SER-109 led to a 32% recurrence rate.  SER-109 was found to be safe and well tolerated. SER-109 has been granted FDA Orphan Drug and Breakthrough Therapy designations.

Synthetic Biologic’s SYN-004 (ribaxamase) is an oral tablet in Phase II development for the prevention CDI and antibiotic-associated diarrhea (ADD). SYN-004 is designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR). Phase IIb results found SYN-004 significantly reduced the risk of CDI by 71% versus placebo (p=0.045). Furthermore, SYN-004 significantly reduced new colonization by vancomycin-resistant enterococci versus placebo (p=0.0002). SYN-004 received Breakthrough Therapy Designation from the FDA for the prevention of CDI.

Other gastrointestinal Phase II pipeline candidates include Synthetic Biologics’ SYN-010 and Osel’s CBM588.

Synthetic Biologics’ SYN-010 is continuing to prepare for the initiation of pivotal Phase II/III clinical trials. SYN-010 is a modified-release formulation of lovastatin lactone designed to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C).

Osel’s CBM588 is an oral Clostridium butyricum strain with a strong safety record undergoing development for antibiotic associated diarrhea and CDI. A Phase II study found CBM588 was safe. CBM588 has also been used safely in all age groups in Japan primarily for diarrheal disorders. Recent nonclinical studies support the use of CBM588 in treating IBS.

Other pipeline candidates to watch include:

  • Osel’s Lactin-V live biotherapeutic product for recurrent UTI and Bacterial Vaginosis in Phase II development
  • Microbiome Therapeutics’ NM504 for prediabetes and Type 2 diabetes; and NM505 for diabetes metformin gastrointestinal intolerance, both microbiome modulators in Phase I development
  • Ritter Pharmaceutical’s RP-G28 an oral galacto-oligosaccharide microbiome modulator for lactose intolerance undergoing Phase IIb/III development
  • Intrexon/Orgenics/Merck’s AG103 novel mouth rinse biotherapeutic for oral mucositis in Phase I development

The latest frontier of human microbiome research involves the development of diagnostic methods and tests that provide accurate assessment of the taxonomic compositions of microbiomes associated with complex samples.

Currently there is a head-to-head market race for two key colorectal cancer diagnostics; Metabiomic’s Colon Polyp and Colorectal Cancer Test and Origin Sciences’ Colorectal Cancer (CCR) Test. Metabiomics’ Colon Polyp and Colon Cancer Test is a non-invasive screening test for the detection of colon polyps and colorectal cancer. The Colon Polyp and Colon Cancer Test detects microbial biomarkers linked to dysbosis and colorectal cancer.

Origin Sciences’ CCR Test is under development for the detection of colorectal cancer in both asymptomatic and symptomatic patients. The CRC Test is designed to detect colorectal cancer using biomarker analysis of patient rectal mucosal samples collected using Origin Sciences’ proprietary OriCol device. A pilot study found that ELISA analysis of protein biomarkers collected with OriCol offers a pre-colonoscopy screening tool in patients referred under a two- week criteria rule. Data from the study suggests that a sensitivity of ≥95% can be achieved.

Although no human microbiome therapeutic or diagnostic product has gained FDA approval, promising new opportunities exist to develop novel therapeutics and diagnostic products across a wide range of diseases/therapeutic areas.

Join us to hear more on the human microbiome pipeline at Arrowhead’s 4th Annual Translational Microbiome Conference taking place in Boston, Massachusetts on April 18-20, 2018. (www.microbiomeconference.com)

Continue reading
2022 Hits

Key Innovations in Microbiome Therapeutics: Translating the Science into the Clinic

These microbiome insights brought to you by Dana Barberio, Principal at Edge BioScience Communications and Arrowhead Publishers and Conferences.

These are glamourous times for the microbiome space. The microbiome has captured the heart of the media, and this red hot scientific area has spawned intense attention from researchers, courtship by investors and a myriad of unique business opportunities and partnerships among companies ranging in size from small start-ups to global pharmaceutical companies. Multiple companies with therapeutics in clinical trials are jockeying for position in a heated race to market, many with their lead candidate targeting Clostridium difficile (C. diff), and with a wide variety of other applications in the queue. Key players in both the scientific and business side of the microbiome space will be gathered together at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference, taking place in Boston, Massachusetts April 11th-13th 2017. Let’s capture an eagle eye view of that conference by looking at recent advances in the microbiome space, and some of the key topics represented at the conference.


Scientists are rapidly discovering the microbiome’s sophisticated and widespread network of interactions that affect human metabolism, neurology, the immune system and skin. The microbiome plays a role in radically different areas of health, such as nutrition, early childhood, hygiene, infectious disease and chronic health conditions. There is evidence that dysbiosis in the gut is a factor in an astounding array of conditions and diseases: inflammatory bowel disease (IBD), atopy, asthma, cancer, obesity, Type 2 Diabetes, fatty liver disease, and neurological disorders.

Hot Areas of Scientific Research
While investors, companies and the media are currently having a love affair with the microbiome (I decline to call it ‘hype’), arguably the science has yet to live up to the expectations. But the scientific foundation is gradually being constructed and is forthcoming with many recent studies. A January 2017 small scale clinical study of Autism Spectrum Disorder provided evidence of improved ASD symptoms resulting from Microbiota Transfer Therapy. A Dec 2016 Caltech study in a mouse model of Parkinson’s disease established that gut bacteria not only contribute to the disease, but apparently play a causal role. There are future market opportunities for treatment of anxiety, depression, and autism that may evolve from an understanding of the science behind gut-brain interactions. Emeran Meyer, MD and professor at UCLA, discusses these topics in his book “The Mind-Gut Connection: How the Hidden Conversation Within Our Bodies Impacts Our Mood, Our Choices, and Our Overall Health.”


IBD has been linked for decades with dysbiosis in the gut microbiome, and more recently scientists have been gaining a deeper understanding. Laying a foundation for defining the mechanisms for this was a March 2014 study by Dirk Gevers of Janssen Human Microbiome Institute with a multi-cohort study comprehensively defining the microbiome diversity landscape of Crohn’s Disease and identification of potential biomarkers. A February 2017 study provided evidence that IBD can be distinguished as two subtypes with distinct microbial signatures, as Crohn’s Disease and Ulcerative Colitis. These microbiome signatures are critical in the development of therapeutic targets.


Another hot area is in the immunotherapy space: predicting patient response and modulating gut bacteria to optimize treatment. Research at MD Anderson Cancer Center in February of 2017 implicated gut bacteria in melanoma patients’ response to PD1 checkpoint inhibitor immunotherapy. Patients that responded to the immunotherapy had a greater diversity of gut bacteria and larger numbers of a specific bacteria than those who did not respond.


With a partnership that will translate microbiome research in immunotherapy into the commercial space, Bristol Myers-Squibb and Enterome entered into an immuno-oncology focused partnership in November of 2016 for the discovery and development of microbiome-derived drug targets and biomarkers to be used in cancer therapeutics and companion diagnostics.


We’ll hear more about these topics at the conference.

Areas with Great Market Potential
From a January 2017 review article by University of Chicago’s Jack Gilbert (conference keynote speaker) and Thomas Kuntz, a hot area in need of more research is in drug response and interaction, as there are already more than 60 drugs known to interact with the microbiome. Enhancement of personalized treatment in a clinical setting will involve a deeper understanding of bacteria’s role in drug metabolism and host variation to drug response, in particular as it corresponds to an individual’s microbiome (and host ‘omes’). For example, a March 2014 study found genes in the gut bacteria Eggerthella lenta that can be used as predictive microbial biomarkers for inactivation of the cardiac drug digoxin, with potential application in studying drug pharmacokinetics and clinical interventions.


Another area with large market potential according to Gilbert and Kuntz is in addressing alternatives to the widespread overuse of broad-spectrum antibiotics and the resulting health-endangering spread of bacterial resistance. One alternative involves targeting specific bacterial pathogens or enzymes with precision antibiotics and therapies. Multiple companies are focused in this area, including Eligo BioscienceSecond GenomeAvidBioticsC3J Therapeutics, and EpiBiome, all of whom have platforms which selectively kill off harmful bacteria while protecting commensal bacteria.


Of course, precision prebiotics and probiotics are another hot focus area, which may involve a systems biology/bioinformatics approach such as used by Seres TherapeuticsEvelo BioSciencesMetabiomics and others.

Empowering Deep Level Understanding with Big Data
If you consider the complexity of genomic and environmental factors such as lifestyle, diet, toxins, polypharmacy, metabolomics, and the gut microbiome, it’s clear that we need some high level bioinformatics to interpret the enormous amount of data for translation into the clinic.
Microbiome-based precision medicine will stem from a deep level understanding of the mechanisms involved in the complexities of host-microbiome interactions. The ultimate level of analysis may come through a systems biology paradigm, which uses mathematical/computational models to analyze large datasets and simulate system behavior with network-based analyses of the interactions between different types of ‘omics’ data (such as genomics, transcriptomics, proteomics and metabolomics), providing novel insight into complex biological systems, new biomarkers and enhanced drug discovery and development. For example, a March 2017 article proposes an ‘omics’-based precision medicine approach for elucidating genomic and metabolic interactions in the microbiome-gut-liver axis. These Big Data practices are expected to transform clinical practice.


Jack Gilbert, one of the keynote speakers at the conference, has a brand-new startup, Gusto, which produces formulations of probiotics. They use a computational modeling platform, GUST+, which predicts bacterial interactions and their effect on the immune system and human health by compiling data from human studies and running thousands of simulations.


One technical hurdle faced in the microbiome therapeutics space is in securing precise taxonomic assignments for bacteria based on sequence alignments, which is a computational challenge for both 16S and shotgun libraries, due to the short Next Gen Sequencing read lengths. This creates an obstacle for identification of reliable clinical biomarkers and hinders follow-up experiments. James White of Resphera BioSciences, at the conference, will discuss a novel approach for high-resolution microbiome profiling of 16S sequence data, which provides accurate species-level characterization.

Databases and Specimen Collection
In the case of Fecal Microbiota Transplantation, the rapid entry into clinical practice preceded the science. The FMT National Registry, a public-private collaboration, was established as a database of clinical and patient-reported outcomes intended to establish the short- and long-term safety and efficacy of FMT.
Another organization, The BioCollective, provides a resource for obtaining human fecal specimens paired with data for use in microbiome research and development, eliminating the need for researchers to recruit individuals for studies.

Frontrunners in Clinical Trials
As leaders in the field rapidly uncover the mechanisms driving the microbiome’s role in disease, the foundation is being established for capitalizing on the science in order to decrease disease and improve health. Farthest along in clinical trials is Rebiotix, with a drug candidate, RBX2660, for recurrent Clostridium difficile in Phase 3 trials. Their Microbiota Restoration Therapy (MRT) platform, which targets other diseases as well, delivers a broad spectrum of live microbes into a patient’s intestinal tract for rehabilitation of the microbiome.


At the conference, we will hear first-hand from a few of the companies in the trenches of clinical trials - Rebiotix, Seres Therapeutics and Vedanta Biosciences - on regulatory considerations, customer expectations, messaging implications, and other critical factors involved in developing and launching microbiome therapeutics.


Partnerships and Regulation
While the scientific and technical resources are critical, we will also hear about the equally critical business side - the role of partnerships as well as regulatory and patent issues.

Since probiotics have widespread acceptance by clinicians and the general population, microbiome therapeutics is at an enviable jumping off point for some microbiome companies. However, the FDA is of course involved in prescription products. The criteria for FDA approval involve defining bacterial colonization, what effect colonization has and how fast it occurs, and the pharmacokinetics/ pharmacodynamics, among other factors. This is for live bacteria. The addition of genetic manipulation adds another level of complexity in gaining approval.


Big Pharma has taken a huge interest in the microbiome space, with numerous partnerships. Among those leading the way was a partnership in 2014 between Second Genome and Pfizer, in which the two companies engaged in a large observational study with the goal of gaining a better understanding of the connection between obesity, metabolic disorders and the microbiome. Three major pharma investment funds have invested in Second Genome. Second Genome is partnering with Monsanto in applying big data science, bioinformatics and machine learning to drive discovery of microbiome-based solutions that can help farmers better manage on-farm challenges.


In 2015, Janssen and Vedanta Biosciences struck a deal involving Vedanta’s out-license of its most advanced clinical candidate VE202: a mix of bacteria from the Clostridia subspecies that are a potential treatment for several IBD disorders: Crohn’s disease and ulcerative colitis.


Most recently, in November of 2016, the aforementioned Bristol Meyers-Squibb and Enterome established an immuno-oncology focused partnership.


Join us to hear more on all of these topics and the many exciting opportunities and challenges in the microbiome space at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. We will see you there!

 

Continue reading
6721 Hits

The Mike Rowe of the Microbiome Space

By Martha Carlin, Chief Executive Revolutionary, The BioCollective

In every industry there are dirty jobs that must be done to fuel the business.  Business Insider recently published “Small World: 20+ Startups Targeting the Microbiome” a review of just some of the exciting new microbiome ventures that are primarily focused in four key areas - diagnostics, genomics, dietary supplements, and intestinal health/disease targeted therapies.[1] These ventures use convenient and available samples for their initial R&D obtained from relationships with universities, hospitals and friends and family. When a promising discovery is made from that initial research, it may be necessary to test it on a larger and more representative population and this is where the The BioCollective comes in. 

Everybody poops.[2] But nobody wants to have to “deal with it.” One of the biggest barriers to accelerating microbiome research is getting a sample from everyone doing their duty! (or dooty depending on the age of your audience!) So we approached the problem from the Pooper’s perspective. We created a kit that is easy to use in the comfort of your home, ick-free and even a little bit fun. There is no scooping, probing, dipping or mixing needed. There are no messy plastic “hats,” bowls or containers to be disposed of. The process is seamless with nothing left behind, so to speak. Our BioCollector patent-pending design collects the entire sample, keeping it viable and ready to leverage into any number of research pipelines. Once the live sample reaches our lab, it is divided into smaller portions and cryopreserved enabling many types of research on the same sample. One sample can generate data from phage to fungi and culture. We are much more than DNA! 

Subject recruitment and sample collection is one of the top five cost drivers in research, but when we do the “dirty job” of providing samples to support microbiome research we can save thousands of dollars from the process. The BioCollective has made pooping a fun and profitable way to participate in microbiome research. We use engaging and innovative ways to get people of all ages and walks of life to become members of The BioCollective with the goal of building a microbiome resource full of samples that are actually representative of the US population. We go beyond the narrow and limited population of WEIRD (white, educated, industrialized, rich and democrat)!

In exchange for providing a sample to aid in research members receive a share of revenue from sample sales and feedback on where their sample is being used. We also provide the member with options for learning what’s in their gut from a basic 16S analysis to whole genome sequencing.  For the super curious, we can provide specialty analysis such as metabolomics, 18S and transcriptomics through our sequencing partners.  

Learn more about what we do and how you can become an active participant in the field of microbiome research at Arrowhead’s 3rd Annual Translational Microbiome Conference, being held April 12-13, 2017 in Boston, MA.

 

[1] https://www.cbinsights.com/blog/microbiome-startups-market-map-company-list/

[2] This is fact, and for an excellent read on this subject, may we suggest “Everyone Poops,” by Taro Gomi, https://www.amazon.com/Everyone-Turtleback-School-Library-Binding/dp/0613685725

Continue reading
2373 Hits

Tailoring Microbiome Interventions: The Intersection of Precision Medicine and the Microbiome

By Carrie Brodmerkel, Senior Director, Systems Pharmacology & Biomarkers, Janssen R&D

The microbiome gets a lot of press these days, from leading scientific journals such as Science publishing a special issue “Microbiota at Work” in April, 1 to articles about fecal microbiome transplants in major newspapers like the Washington Post.2 Many articles tout the need for a healthy gut microbiome and that the diversity of the gut microbiome is what maintains not just gut health but overall health. But for all of the hype, what do we really know about what a healthy microbiome looks like? What do we really know about the impact of the microbiome on health and disease? Is there a universal definition of a healthy microbiome or is it more likely that the each person has his or her own unique healthy gut microbiome?

A study published in 2015 in Science Advances studied the fecal, oral and skin microbiome of an Amerindian tribe, the Yanomami, who were completely isolated from the Western world.3 The researchers found that the Yanomami had the highest levels of human microbial diversity ever reported. They also don’t suffer from Western diseases like cardiovascular and metabolic disease or autoimmune and inflammatory diseases. Does this infer that gut microbial diversity equates to better health and less disease? That has not yet been proven and it may be that the microbiome in this tribe works in conjunction with a far different lifestyle and lack of chemical and pharmaceutical impacts and interventions to support a lack of disease. Still it drives the question of whether personalized cocktails of microbes will be needed to achieve optimal gut health for a given individual or group of individuals with similar microbiomes?

This collision of microbiome research and the precision medicine space, and the potential need for patient selection and personalization of microbiome therapies, will play out as microbial based therapeutics begin to hit the clinic. Evidence supporting this need already exists from fecal microbial transplant studies in C. difficile and inflammatory bowel disease where the response rates in an unselected population of patients leaves opportunity for improvement. Efforts to understand the functional effects of the microbes that inhabit the human gut and determining which promote health and which promote disease will be essential in unraveling the microbial communities necessary to promote health at the population or cohort level.

Hear more about Janssen’s efforts to define patient stratification strategies and personalized medicine in the age of microbial-based therapeutics at Arrowhead’s 3rd Annual Translational Microbiome Conference, being held April 12-13, 2017 in Boston, MA. For more information, visit: http://www.microbiomeconference.com

1 Science Magazine April 2016 http://science.sciencemag.org/content/352/6285

2 https://www.washingtonpost.com/news/speaking-of-science/wp/2016/04/28/scientists-think-theyve-found-the-secret-to-better-poop-transplants/?utm_term=.91f00d298c91

3 http://advances.sciencemag.org/content/1/3/e1500183.

Interestingly, despite their isolation and no known exposure to antibiotics, it was found that the tribe harbored bacteria that carried functional antibiotic resistance genes, including those that confer resistance to synthetic antibiotics and are syntenic with mobilization elements.

Continue reading
2118 Hits

Interview with Mollie Roth: Executive Director of The Microbiome Coalition (TMBC)

 

Interview with Mollie Roth, JD

Executive Director of The Microbiome Coalition (TMBC)

 

What is The Microbiome Coalition and what’s its goal?

The Microbiome Coalition (TMBC) represents a variety of commercial entities working toward commercial success in the microbiome field, united by their desire to promote greater public understanding of the role of the microbiome in human health and wellness, and the desire to advance appropriate regulation, needed investment and required infrastructure.

Recognizing that a shift in how microbiome based medicine and research is implemented will not happen simply because a body of scientific evidence suggests it should, TMBC has identified key goals to support and advance the industry, including: Education, Regulatory Engagement and Standards. You can learn more about what we are doing on all three fronts at http://www.themicrobiomecoalition.com/

 

How did TMBC come to be formed? 

Although I started my career as a litigator for the pharmaceutical industry, I have always had an affinity for making business run better. I spent 10 years working with a precision medicine consulting company helping pharma drug development teams understand how to co-develop and launch companion diagnostics.

In early 2013, I started working as a consultant in the microbiome space and became interested not only in the vast body of research that was happening across multiple industries – pharmaceutical, diagnostic, consumer products and nutrition – but in the challenges for companies to become a commercial success. Many of the hurdles and challenges this industry faces mirror exactly the experience in the precision medicine field – an unclear regulatory path, unclear business models, a lack of standards, differing reference databases among others.

It was my opinion, based on my experience in the precision medicine field, that a coalition of companies in this space could better address and overcome these challenges than any one company could. Thankfully the founding companies agreed with me and TMBC was born.

 

You said one of TMBC's goals pertains to standards, is there a problem with standards in the microbiome space?

In scientific research, standards allow for and ensure quality in research and the generation of quality evidence that can be compared across researchers and companies. Absent uniform standards, the quality of scientific research can be uneven and lacking in credibility, making it difficult to make confident, concrete assertions or predictions regarding evidence for improving practice or consumer outcomes.

For example, in the precision medicine space, we saw the lack of standards cause issues when it became apparent that there were no standardized practices for how samples being used to generate clinical data for diagnostic tests were handled. There are a number of groups already hard at work on two distinct standards issues in the microbiome space – how samples are handled and sequenced as well as how the vast volume of information generated in this space is processed. 

TMBC will serve as a clearinghouse for these activities already underway and will bring these disparate groups to the table to ensure they are engaging with each other so the industry ends up with a set of conformed standards, rather than numerous sets of non-interoperable standards.

 

What companies formed TMBC?

The founding companies are a visionary set of innovators who quickly understood the need for a coalition of companies working toward commercial success in the microbiome space and have provided seed support and substantial resources to get the coalition off the ground. They include AOBiome, Whole Biome, CosmosID, Abbott Nutrition, The Mayo Clinic, Diversigen and Second Genome.

 

How important are collaborations in the microbiome space?

 As incredibly important as they are in any area of new scientific research!

There are literally hundreds of small startup companies making incredibly exciting discoveries with regard to the microbiome, but without the resources or global reach to complete their research or get products approved and launched. Collaborations with larger companies, carefully crafted to ensure a win-win, are not only vital but imperative to move this space forward.

Further, now that we are a few years into the “age of the microbiome” we are starting to see a convergence between microbiome therapies and precision medicine, as companies consider how patients might need to be stratified based on their microbiome to determine who best to treat. The business models of how pharma and diagnostic companies can best collaborate and work together will continue to be vitally important as these two spaces continue to merge.

 

Is membership in TMBC open and to whom?

Membership in TMBC is open and we welcome any company, association or individual with an interest in advancing the commercial viability of microbiome based therapies, diagnostics, consumer or nutrition products to address and improve human health and wellness. You can learn more about membership options at http://www.themicrobiomecoalition.com/become-a-member/

 

Continue reading
2521 Hits

The Medium is the Message

I write this, the inaugural blog post for Arrowhead’s 3rd Annual Translational Microbiome Conference, as I listen to election result returns and find cheer in the gains that my current home state of Arizona has made in voting in a minimum wage increase and in voting out an antiquated (literally and figuratively) sheriff. But this election has far greater implications for us all in the scientific community.

It is clear that science is having a hard time gaining a foothold these days. The good news is that the Pew Research Center found that 79% of 2,000 people polled think science has “made life easier for most people” and 71% believe that investment in science pays off. The bad news is that as soon as a scientific question becomes politicized, it seems no amount of evidence can sway people’s minds. For example, over 50% of the people surveyed believe that GMO foods are generally unsafe whereas 88% of scientists polled think they are generally safe.1 My very unscientific personal poll in asking friends and colleagues about GMO foods quickly reveals that the question of GMO food is almost universally confused with the issue of Monsanto and GM wheat. The fact that we believe in the value of science does not necessarily reflect an understanding of its nuances.

How and why certain scientific issues – GMO foods, vaccines, climate change among others – become politicized is beyond the limits of this post but is driven in some large part by how the media reports on scientific research.2 And I think we in the microbiome community need to be aware of the potential dangers of microbiome-based research becoming tainted by a whiff of spoiled milk.

Spoiled milk, what am I on about?

Earlier this year health officials at the CDC announced they had discovered a pathogenic connection between raw milk from a Pennsylvania dairy and two illnesses in 2014 — one in California and the other in Florida. If you are not aware, the raw milk community is a vociferous and outspoken one, and the backlash was quick. When the CDC stated that the samples were “closely related genetically” and that the raw milk was the “likely source” of the illnesses, opponents were fast to pounce and ask why the CDC could not say they were 100% certain. 100% certainty is an unattainable goal in science, as we know, but that does not mean the general public will understand that.

So when that same public goes from demanding 100% certainty that a specific bacteria in raw milk caused some illness, how are they likely going to react to the idea of “poop in a pill” or fecal microbiome transplants? Again, my utterly unscientific poll of my Facebook cohort, and their reactions to my posts on this subject, suggest “not very well” is the answer. And how the media ultimately portrays this research will have a substantial impact on how it is received, and where it brushes up against hot button topics – like access to raw milk – it is likely to become a hot button issue itself.

The role of the media, and how they report on the microbiome and their role in the messages the public receives, will be explored by moderator Colleen Cutcliffe, co-founder and CEO of Whole Biome, in her panel “The Media and the Microbiome” at Arrowhead’s 3rd Annual Translational Microbiome Conference, being held April 12-13, 2017 in Boston, MA USA.

We invite you to join us and help guide the conversation.

1 http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/

2 Although I will recommend the very compelling albeit slanted read, Science Left Behind: Feel-Good Fallacies and the Rise of the Anti-Scientific Left by Alex B. Berezow, a microbiologist, and Hank Campbell.

Continue reading
2181 Hits

Banking Your Personal Biome

(Guest Bloggers, Sasha Lieberman, Nonprofit Management Fellow and Carolyn Edelstein, Director of Policy and Global Partnerships, OpenBiome)

Mark Smith and James Burgess were inspired to found OpenBiome after a family friend who had suffered with repeated C. difficile infections shared his story of having to resort to performing a DIY fecal transplant at home. Since its founding in 2012, OpenBiome has been committed to enabling safe access to fecal microbiota transplantation (FMT) by providing rigorously screened, ready-to-use microbiota preparations for use in FMT and by catalyzing research into the human microbiome.

This year, OpenBiome launched PersonalBiome, a pilot service that allows individuals who are at risk of contracting C. diff to preserve a copy of their healthy microbiome. In the event that these individuals do end up experiencing recurrent C. diff infections, participants can retrieve their sample from their PersonalBiome bank to repopulate their gut with their own healthy microbial community. PersonalBiome pushes OpenBiome’s mission to provide safe microbiota treatments from its pool of universal stool donors forward by expanding the available options for repopulating the gut microbiome following a C. diff infection.

In some ways, the service resembles that of private umbilical cord blood banking. A practice that began in the early 1990s, cord blood banking is now undertaken by a network of over 100 cord blood banks and transplant centers that have stored over 400,000 units of cord blood worldwide. The vast majority of banked cord blood is for use by unrelated donors, but private banks have arisen to give families the option of storing their own cord blood, a service that is most useful for those with family members who have a current or potential need for a stem cell transplant.

Current FDA regulations governing FMT only permit physicians to treat patients with FMT outside of a clinical trial, if the patient experiences repeated, unresolvable C. diff. These regulations apply equally to one’s own stool as well as stool from a universal bank. However, co-founder and executive director James Burgess, featured in this recent FastCompany article about the PersonalBiome pilot project, envisions a future in which high-risk patients can bank their microbiomes to help prevent and treat other microbiome-associated diseases.

Individuals who would like to learn more about participating in the PersonalBiome pilot launch should contact This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.openbiome.org/personalbiome. To learn more about OpenBiome and what we do, visit www.openbiome.org.

Continue reading
3882 Hits
0 Comments

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

Arrowhead Publishers & Conferences
PO Box 96
7730 Laredo Drive, #96
Chanhassen, MN 55317
866-945-0263
enquiries@arrowheadpublishers.com

PRIVACY POLICY

Continuing Medical Education Credits Now Available for this Event

Joint-Providership Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Office of Continuing Medical Education of the University of Virginia School of Medicine and Arrowhead Publishers. The Office of Continuing Medical Education of the University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

The University of Virginia School of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity. (The number of credits offered for this event is subject to change dependent upon future additions/revisions to the agenda.)

The University of Virginia School of Medicine, as accredited provider, awards 8 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)TM ) to a participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

MOC Part II (ABMS) is awarded up to 8 Self-Assessment Credit (transcript awards both MOC and AMA) per learning activity within. Through the American Board of Medical Specialties (ABMS) and Association of American Medical Colleges’ (AAMC) joint initiative to create a wide array of Maintenance of Certification (MOC) Activities. CardioVillage has met the MOC requirements as a MOC Part II CME activity by the following ABMS Member Boards:

MOC Part II CME Activity

  • American Board of Internal Medicine
  • American Board of Pediatrics

Shahram Lavasani, Ph.D.

Founder, Chief Executive Officer and Chief Scientific Officer
Immune Biotech

Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University in Sweden while studying the immunoregulation and immunotherapies in multiple sclerosis (MS). With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in MS by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnificTM has been designed to address the underlying causes of IBS and successfully launched to European market in October 2019.

Scott Jackson, Ph.D.

Group Leader, Complex Microbial Systems
NIST (National Institute of Standards & Technology

In this current role, Scott is leading international efforts to improve microbiome and metagenomic measurements by organizing inter-lab studies, developing reference materials and reference methods, and developing in vitro tools that allow us to better understand microbial community resilience and evolution.

Rachel Clemens, Ph.D.

Commerical Innovation Manager, Life Science Lead
ISS US National Lab, Center for Advancement in Science in Space

Rachel Clemens has focused her career on advancing life science research and product development through experiments in space. In her current role as a Commercial Innovation Manager at the ISS US National Lab, she brings life science research to low earth orbit. She leads partnership development specifically with life science companies – from biotech start-ups to large pharmaceutical companies. She is eager to entertain even the craziest of ideas and passionate about finding novel solutions to Earth-bound problems.

Lynne Elmore, Ph.D.

Director, Translational Cancer Research Program
American Cancer Society

Lynne Elmore, PhD, is the director of the Translational Cancer Research program in the Extramural Grants department of the American Cancer Society (ACS). She manages a research portfolio focused on cell biology, infectious disease, the microbiome, molecular genetics, and cancer drug discovery.

Garth Ehrlich, Ph.D.

Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery
Drexel University College of Medicine

Dr Ehrlich is Professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University College of Medicine (DUCOM) in Philadelphia, PA, USA. Dr. Ehrlich is also the founder and director of three Research Centers of Excellence in the Institute for Molecular Medicine and Infectious Disease: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms.

He also directs Drexel University’s Core Genomics Facility and the Meta-Omics Shared Resource for the Sidney Kimmel Cancer Center – an NCI-designated Cancer Center.

Momo Vuyisich, Ph.D.

Chief Scientific Officer
Viome

Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven personalized nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio.

Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today.

Nancy Caralla

Founding President, Executive Director
C Diff Foundation

Nancy C Caralla is a three-time Clostridioides difficile infection (CDI) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 30 years in international construction management. Over the past several years, Nancy, in partnership with C Diff Foundation members, has focused on raising C. difficile awareness through education and advocating for Clostridium difficile infection prevention, treatments, clinical trials, AMR, and environmental safety worldwide. The C Diff Foundation is a non-profit organization that takes great pride in its volunteers, chairpersons, and committees.

Rachel Teitelbaum, Ph.D.

Chief Executive Officer
Hervana

Rachel Teitelbaum, PhD is the founder and Chief Executive Officer of Hervana Bio Ltd. Dr. Teitelbaum earned her Ph.D. in microbiology and immunology at the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Her academic research career spans more than 15 years, with a focus on research in infectious diseases, in particular relating to the host-pathogen interface, elements of the immune response to intracellular pathogens, the development of animal models of infection and the development of vaccines, in particular for providing effective mucosal immunity. With the founding of Hervana Bio Ltd, Dr. Teitelbaum has applied some of these principles to developing a probiotic therapeutic platform in Women’s Health applications, including the development of a non-hormonal, long-acting biologic contraceptive.

Sonia Timberlake, Ph.D.

Vice President of Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Dae-Wook Kang, Ph.D.

Assistant Professor, Department of Civil & Environmental Engineering
University of Toledo

Dr. Kang received his BS and MS in Civil and Environmental Engineering from the Seoul National University and his PhD (also in Civil and Environmental Engineering) from the University of Wisconsin-Madison. Prior to joining the University of Toledo in 2019, Dr. Kang was a research scientist in the Biodesign Swette Center for Environmental Biotechnology at the Arizona State University where he was involved in groundbreaking work to establish the relationships between human gut microbiota and autism spectrum disorders. His broad research interests are employing multi-omics technologies and bioinformatics to advance understanding of the role of microbiota on human health, environment, and engineering systems, and eventually to improve human public health and environment sustainability.

Amy Feehan, Ph.D.

Research Scientist
Ochsner Health System

Dr. Feehan is an early stage investigator who received her BS and PhD in Neuroscience from The Brain Institute at Tulane University in New Orleans. She has conducted research in humans and rodents covering topics ranging from drug development of novel endomorphin analogs for pain, to sleep and circadian rhythms research and most recently the gut-brain axis and infectious disease. Her doctoral work led to two patents for a compound that reverses both acute and chronic pain with no observable risk of addiction. She currently works as a research scientist in the Infectious Disease department at Ochsner in New Orleans designing and executing investigator-initiated clinical trials.

Sangeeta Khare, Ph.D.

Research Microbiologist, Division of Microbiology, National Center for Toxicological Research
US Food & Drug Administration

Dr. Sangeeta Khare is a Research Microbiologist in the Division of Microbiology, at National Center for Toxicological Research, Food and Drug Administration. Dr. Sangeeta Khare leads an active team with a research emphasis on host-pathogen and host-microbiome interaction during perturbations with xenobiotic agents (nanoparticles, antibiotics and other drugs, natural products and additives). The main focus of Dr. Khare’s research group is on establishing innovative parameters of host intestinal toxicity.

Julius Goepp, MD

Chief Executive Officer
Scaled Microbiomics

Dr. Goepp is the inventor of “Systems and Methods for Altering Microbiome to Reduce Disease Risk and Manifestations of Disease,” filed as a PCT patent with USPTO on August 27, 2017 and assigned to Scaled Microbiomics, LLC. He has spearheaded the development of Scaled Microbiomics to date, including developing a research team, equipping a laboratory, designing the experiments that produced supporting data on use of IgY in microbiome applications, and interpreting the results.

Ze'ev Ronai, Ph.D.

Professor
Sanford Burnham Prebys Medical Discovery Institute

Ze'ev Ronai obtained his Ph.D. in 1985 from The Hebrew University, Jerusalem Israel and performed his postdoctoral research with I.B. Weinstein at the Cancer Center of Columbia University in New York. He established the Molecular Carcinogenesis Program at the American Health Foundation in Valhalla, New York, and in 1997 moved to the Ruttenberg Cancer Center at Mount Sinai School of Medicine in New York, where he was a tenured professor up to 2005. During 2004, Dr. Ronai moved to Sanford Burnham Prebys Medical Discovery Institute (formerly known as Sanford-Burnham Medical Research Institute) in La Jolla CA, where he is a Professor. He served as the Director of the Signal Transduction Program (2005-2013), as the Deputy Director for the Cancer Center (2008-2014), and as the Scientific Director for the La Jolla site (2014-2016). He established a cancer center at the Technion in Israel (Technion Integrated Cancer Center), while maintaining his activities at SBP (2016-2018). He is currently Chief Scientific Advisor and Professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), La Jolla CA.

Cecile Clavaud, Ph.D.

Project Leader in Skin Microbiome, L'Oreal Advanced Research
L'Oreal

Research and Innovation, France Dr. Clavaud's initial expertise is chemistry and biochemistry to design new radiolabelled probes for medical imaging (Commissariat à l’Energie Atomique, Saclay, FRANCE) followed by four years post doc in the Aspergillus Unit (Institut Pasteur, Paris, FRANCE) to characterize the molecular mechanisms involved in the fungal cell wall polysaccharides biosynthesis. Dr. Clavaud joined L’Oréal Research and Innovation in 2011, to work in an open innovation mode, establishing partnership with international academic experts in the skin and scalp microbiome field. At that stage, she explored the ecology of skin microbiota members (bacteria, fungi and viruses) observed in various skin physio-pathologies and body sites in order to identify key determinants involved in the interaction with skin. Since 2017, she has been involved in building a laboratory dedicated to the skin – microbiota interactions in 3D reconstructed skin models, to better understand how commensal microbiota can impact positively the skin barrier function and the skin quality. Today, she is leading transformation projects turning the recent microbiome knowledge into anti-aging applications.

Anandh Babu Pon Velayutham, Ph.D.

Associate Professor, Department of Nutrition and Inegrative Physiology
University of Utah

Dr. Anandh Babu Pon Velayutham is an Associate Professor in the Department of Nutrition and Integrative Physiology at the University of Utah. His research focuses on identifying novel dietary compounds for the prevention of vascular disease in diabetes and metabolic syndrome. His current research examines the vascular effects of blueberries and strawberries with special emphasis on the microbial metabolites of berry anthocyanins and the molecular signaling mechanisms involved. Dr. Velayutham's research aims to understand the causal association between dietary berries, gut microbiome and vascular health.

Sara Ferrando Martinez, Ph.D.

Research Scientist
AstraZeneca

Dr. Sara Ferrando-Martinez is a Research Scientist at AstraZeneca. Sara is an immunologist that focused on understanding the mechanisms underlying the deterioration of the immune system and how to rejuvenate and recover immune responses as a strategy for immunotherapy. Within AZ Sara is trying to uncover the link between microbiome, microbiome-related products and immune modulation and its impact in health and disease.

A. Stewart Campbell, Ph.D.

VP, Early Stage Development
Axial Biotherapeutics

Dr. Campbell brings more than 25 years of drug discovery and development experience to the team. He has built and led R&D teams involved in a variety of environments from early stage research through to advanced clinical development in small start-ups to mid-sized companies. With capable colleagues he has been fortunate to have triaged several drug candidates from discovery to clinical proof-of-concept in multiple therapeutic areas. He received a Ph.D. in Organic Chemistry from the Queen’s University, which was followed by post-doctoral research at Duke University. He has consulted for several start-up companies in multiple technology and therapeutic areas in the Greater Boston area and is co-inventor on more than 15 issued patents.

Gregg Silverman, MD

Professor of Medicine & Pathology
NYU School of Medicine

Dr. Silverman is Professor of Medicine and Pathology, Associate Director of the Division of Rheumatology, and the Director of the Laboratory of B-cell Immunobiology at the NYU School of Medicine. He is an elected member of AOA, ASCI and the Henry Kunkel Society. After training in Internal Medicine at UCSD, he was a fellow at The Scripps Research Institute in rheumatology and clinical immunology, with a focus on molecular immunology and the structural basis of immune recognition. He has authored over 160 publications and he is on the editorial board of several prestigious journals. Work in his lab is highly translational, with a special interest in B cells and the properties of autoantibodies. and more recently the contributions of the gut microbiome to autoimmune disease.

Mahmoud Ghannoum, Ph.D.

Professor, Department of Dermatology
Case Western University and University Hospitals Cleveland Medical Center

Dr Mahmoud Ghannoum received MSc in Medicinal Chemistry and PhD in Microbial Physiology from University of Technology in England, and an MBA from the Weatherhead School of Management at Case. Presently he is a tenured Professor and Director of the Integrated Microbiome Core and Center for Medical Mycology, Case Western Reserve University and University Hospitals Cleveland Medical Center (UH) where he established a multidisciplinary Center of Excellence that combines basic and translational research investigating medically important fungi from the test tube to the bedside. More recently he pioneered the studies on the fungal communities residing in our body and coined the term ‘Mycobiome”.

He is also a fellow of the Infectious Disease Society of America and past President of the Medical Mycological Society of the Americas (MMSA). In 2016, Dr Ghannoum received the Rohda Benham Award presented for his continuous outstanding and meritorious contributions to medical mycology from the Medical Mycological Society of the Americas and he also received the Freedom to Discover Award from Bristol-Myers Squibb for his work on microbial biofilms. In 2017, he was inducted as a fellow of the American Academy of Microbiology. Beside his academic career Dr. Ghannoum is an entrepreneur-scientist who launched a number of companies focusing on the treatment of biofilm infections as well as microbial dysbiosis as it relates to gut health.

Pamela Silver, Ph.D.

Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology
Harvard Medical School

Pamela Silver received her BS in Chemistry and PhD in Biochemistry from the University of California where she was an NIH Pre-doctoral Fellow. She was a Postdoctoral Fellow at Harvard University in the Dept of Biochemistry and Molecular Biology where she was a Fellow of the American Cancer Society and The Medical Foundation. Subsequently, Pam was an Assistant Professor in the Dept of Molecular Biology at Princeton University and then moved to the Dana Farber Cancer Institute where she was a Professor in the Dept of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Pam became one of the founding members of the Department of Systems Biology at Harvard Medical School and the first Director of the Harvard University PhD Program in Systems Biology and one of the first members of the Harvard University Wyss Institute for Biologically Inspired Engineering. Her work has been recognized by an Established Investigator of the American Heart Association, a Research Scholar of the March of Dimes, an NSF Presidential Young Investigator Award, Claudia Adams Barr Investigator, an NIH MERIT award, the Philosophical Society Lecture, a Fellow of the Radcliffe Institute, and election to the American Academy of Arts and Sciences. She is among the top global influencers in Synthetic Biology and her work was named one of the top 10 breakthroughs by the World Economic Forum. She serves on numerous public and private advisory boards including the board of the Internationally Genetics Engineering Machines (iGEM) Competition, and she is the co-founder of several biotech companies.

NEW VIRTUAL EVENT

The 6th Annual Translational Microbiome Conference, scheduled for April 21-23 in Boston, MA has been replaced with a Virtual Conference that will be taking place April 21-24, 2020. Registered attendees will have full access to the ON-DEMAND full broadcast after the event.

REGISTRATION IS NOW OPEN. REGISTER NOW!

The full agenda and timeline is NOW AVAILABLE. CLICK HERE for details.